Author:
Kay Alasdair G.,Long Grace,Tyler George,Stefan Andrei,Broadfoot Stephen J.,Piccinini Anna M.,Middleton Jim,Kehoe Oksana
Publisher
Springer Science and Business Media LLC
Reference81 articles.
1. Pincus, T., Kavanaugh, A. & Sokka, T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the ‘side effects’ or risks of RA leads to underestimation of the benefit/risk of therapies. Clin. Exp. Rheumatol. 22, S2–11 (2004).
2. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011).
3. Smolen, J. S. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210–221 (2009). Erratum in: Lancet.; 374(9699), 1422 (2009).
4. Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023–2038 (2016). Erratum in: Lancet. 388(10055), 1984 (2016).
5. Finckh, A., Simard, J. F., Gabay, C. & Guerne, P.-A. SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann. Rheum. Dis. 65, 746–752 (2006).
Cited by
113 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献